Submitted abstractsNSCLC, metastatic1296TiP - A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
NSCLC, metastatic
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2016 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.